NEW YORK (GenomeWeb) – Metabolon said today it has entered a joint laboratory licensing agreement with Zhejiang Dian Diagnostics, an independent Chinese medical laboratory firm.
Under the terms of the agreement, Dian will install Metabolon's Discovery HD4 metabolomics platform in its Hangzhou laboratory, and will commercialize Metabolon's metabolomics-based products and services throughout China. Dian will sell Metabolon's products for research in pharmaceutical, consumer goods, agricultural, academic, and clinical applications, and to support large-scale population studies in China.
Additional licenses to new tests and products can be added to the agreement in the future, the companies said. Financial and other terms of the agreement were not disclosed.
"Dian's collaboration with Metabolon… will bring a cutting-edge platform to the Chinese market to assist clients and promote the application of advanced clinical tests," Dian Chairman and CEO Chen Haibin said in a statement.
"Establishing the Discovery HD4 platform in China allows Metabolon to better serve current and future customers in this significant market," added Metabolon CEO John Ryals. "Dian is well-positioned as a leader in clinical and research markets, and we look forward to working with them to expand our opportunities in life sciences research, commercial, diagnostics, and precision medicine markets."